Advance Discovery

Through CancerLinQ Discovery®, we provide access to de-identified real-world data sets to researchers from CancerLinQ practices, academia, government, cancer research centers, medical societies and other nonprofit organizations that can generate practical knowledge to shape the future of cancer care. The data sets include curated sets of aggregated, de-identified data on a variety of cancer types that can be studied to improve patient care delivery.

With CancerLinQ Discovery, we are able to expand the information network to anyone in the cancer community.
Dr. Robert Miller, Medical Director, CancerLinQ

Request Access

To learn more about requesting data from CancerLinQ Discovery®, visit or email us at

Alternative Treatments icon
Compare the effectiveness and value of alternative treatment options
Study Cancer Care Icon
Study the use of cancer treatments in populations typically excluded from clinical trials to generate new knowledge to improve patient care.
Clinical Guidelines Icon
Deliver insights to inform and revise practice guidelines and quality measures
Patients enrolled in clinical trial large icon
Patients who enroll
in clinical trials
learn from icon
Patients CancerLinQ can
learn from
diagnosed each year icon
Americans diagnosed with cancer each year
survivors icon
alive today

A Community That Learns Together

CancerLinQ Discovery is building a community that learns together and shares insights to improve patient care and outcomes. In 2016, Founding Enterprise Partner AstraZeneca became the first industry strategic partner to join in the mission of CancerLinQ Discovery. Since then, CancerLinQ has established collaborations with government agencies, including the U.S. Food and Drug Administration, medical specialty societies, and other health technology companies. Interested in joining their collaborative community of learning? Email